Raloxifene

USDailyMed:Raloxifene AU:X (High risk) G03XC01(WHO) US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]-methanone 84449-90-1Yas HCl:82640-04-8 5035 2820 DB00481Y 4859Y YX9162EO3Ias HCl:4F86W47BR6 D08465as HCl:D02217 CHEBI:8772Y ChEMBL81Y RAL (PDBe,RCSB PDB) DTXSID3023550 Interactive image O=C(c1c3ccc(O)cc3sc1c2ccc(O)cc2)c5ccc(OCCN4CCCCC4)cc5 InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2YKey:GZUITABIAKMVPG-UHFFFAOYSA-NY Raloxifene, sold under the brand nameEvistaamong others, is a medication used to prevent and treatosteoporosisinpostmenopausalwomen and those onglucocorticoids.For osteoporosis it is less preferred thanbisphosphonates.It is also used to reduce the risk ofbreast cancerin those at high risk.It is takenby mouth. Commonside effectsincludehot flashes,leg cramps,swelling, andjoint pain.Severe side effects may includeblood clotsandstroke.Use duringpregnancymay harm the baby.The medication may worsenmenstrual symptoms.Raloxifene is aselective estrogen receptor modulator(SERM) and therefore a mixedagonist–antagonistof theestrogen receptor(ER).It hasestrogeniceffects inboneandantiestrogeniceffects in thebreastsanduterus. Raloxifene was approved for medical use in the United States in 1997.It is available as ageneric medication.In 2020, it was the 292nd most commonly prescribed medication in the United States, with more than 1million prescriptions.